HDAC-IN-91

• Description:

  HDAC-IN-91 is a multiple inhibitor of HDAC (IC50 = 134.22 nM for HDAC1, 66.29 nM for HDAC2), carbonic anhydrase (CA) (Ki = 72.03 nM for CA IX, 50.76 nM for XII), and tubulin polymerization (IC50 = 2.56 μM) . HDAC-IN-91 inhibits PARP1 and increases the Bax/Bcl-2 ratio. HDAC-IN-91 blocks the cell cycle at the G2/M phase and induces apoptosis through a mitochondrial apoptosis activation mechanism. HDAC-IN-91 can exert potent cytotoxic activity through tubulin polymerization inhibition. HDAC-IN-91 can be used in breast, colorectal, cervical and lung cancer research[1].

• UNSPSC:

  12352101

• Target:

  Apoptosis; Bcl-2 Family; Carbonic Anhydrase; Caspase; HDAC; Microtubule/Tubulin; PARP

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  BrC1=CC=C (C (/C=C/C2CC=C (OCC (NC3=CC=C (S (N) (=O) =O) C=C3) =O) C=C2) =O) C=C1

• Molecular Formula:

  C23H21BrN2O5S

• Molecular Weight:

  517.39

• References & Citations:

  [1]Mohamed MFA, et al. Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase‑carbonic anhydrase inhibitors with potential anti-tubulin activity. Bioorg Chem. 2025 Jun 20;163:108694.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Bax; Bcl-2; CA IX; CA XII; Caspase 7; Caspase 9; HDAC1; HDAC2